Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Pharming Group N.V.
  6. News
  7. Summary
    PHARM   NL0010391025

PHARMING GROUP N.V.

(PHARM)
  Report
Real-time Euronext Amsterdam  -  05:28 2022-09-28 am EDT
1.054 EUR   -1.22%
03:36aPharming Group Says Application for Primary Immunodeficiency Drug Accepted for Priority Review by FDA
MT
09/23Pharming N : Halfjaarlijkse financiële verslaggeving
PU
09/21Pharming N : BlackRock Inc. - Pharming Group N.V. - Leiden
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pharming : PHGUF: 2014 Results; Looking for U.S. Ruconest Traction; Reiterate Buy

03/06/2015 | 11:04am EDT

Biotech company Pharming Group NV announces the analyst report completed by Joseph Pantginis, Ph.D. from Roth Capital Partners is published.

Pharming reported financial results for 2014, posting EPS of €(0.014) vs. our estimate of €(0.01) and revenues of €21.3 million vs. our estimate of €28.6 million. Royalties from first sales of Ruconest in the U.S. contributed €0.3 million. Pharming ended the year with €34.4 million in cash.

Visit our Analyst Coverage & Reports page to read more reports by ROTH Capital Partners.

Contact

Sijmen de Vries, CEO: T: +31 (0)71 524 7400

"This update is for informational purposes only and is not viewed by Pharming to be of a price sensitive nature"

distributed by

© Publicnow 2015
All news about PHARMING GROUP N.V.
03:36aPharming Group Says Application for Primary Immunodeficiency Drug Accepted for Priority..
MT
09/23Pharming N : Halfjaarlijkse financiële verslaggeving
PU
09/21Pharming N : BlackRock Inc. - Pharming Group N.V. - Leiden
PU
09/16Pharming N : BlackRock Inc. - Pharming Group N.V. - Leiden
PU
08/04Transcript : Pharming Group N.V., H1 2022 Earnings Call, Aug 04, 2022
CI
08/04Pharming N : Group reports financial results for the first half of 2022
PU
08/04Pharming Group N.V. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
08/04PHARMING GROUP N.V. : Corporate officers' Statement : transactions ..
CO
08/04PHARMING GROUP N.V. : Half-year results
CO
08/04PHARMING GROUP N.V. : Press Release
CO
More news
Analyst Recommendations on PHARMING GROUP N.V.
More recommendations
Financials
Sales 2022 205 M 196 M 196 M
Net income 2022 15,2 M 14,6 M 14,6 M
Net cash 2022 79,3 M 76,1 M 76,1 M
P/E ratio 2022 29,6x
Yield 2022 -
Capitalization 696 M 668 M 668 M
EV / Sales 2022 3,02x
EV / Sales 2023 2,24x
Nbr of Employees 277
Free-Float 98,2%
Chart PHARMING GROUP N.V.
Duration : Period :
Pharming Group N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PHARMING GROUP N.V.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 1,07 €
Average target price 1,78 €
Spread / Average Target 66,8%
EPS Revisions
Managers and Directors
Sijmen de Vries Chairman-Management Board, CEO & CFO
Jeroen Henk Wakkerman Chief Financial Officer
Paul Jai Sekhri Chairman
Anurag Relan Chief Medical Officer
Robert Friesen Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
PHARMING GROUP N.V.37.68%668
JOHNSON & JOHNSON-3.58%433 657
ELI LILLY AND COMPANY11.32%295 599
ROCHE HOLDING AG-17.54%259 622
ABBVIE INC.4.67%250 575
PFIZER, INC.-25.33%247 449